Exosomes: Traversing the blood-brain barrier and their therapeutic potential in brain cancer
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2025
DOI: 10.1016/j.bbcan.2025.189300 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2025. Verfasst von Xiaopei Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Eshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, N…. Hauptthemen laut MEDLINE: Blood-Brain Barrier, Exosomes, Brain Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 167 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, Eshelman Institute for Innovation, University of North Carolina at Chapel Hill, Accelerate Brain Cancer Cure.
Abstract (Originalsprache)
The blood-brain barrier (BBB) presents a major challenge for the effective delivery of therapeutic agents to the brain tumor cells from the peripheral blood circulation, making the treatment of central nervous system (CNS)-related cancers more difficult and resistant to both standard treatments and emerging therapies. Exosomes, which serve as messengers for intercellular communication throughout the body, can naturally or be modified to penetrate the BBB. Recently, exosomes have been increasingly explored as an invasive or non-invasive approach for delivering therapeutic agents to the CNS. With their low immunogenicity, ease of modification, excellent cargo protection, and inherent ability to cross the BBB, exosomes hold great promise for revolutionizing targeted therapy for CNS-related diseases, including brain cancer. In this review, we highlight recent discoveries and insights into the mechanisms exosomes use to penetrate the BBB, the methods they employ to payload diverse therapeutics, and their roles in transporting therapeutic compounds for brain cancer and other neurological disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: xpzhang@email.unc.edu.
- Department of Pediatric Hematology/Oncology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
- Steindler Consulting, Boston, MA, USA; Eshelman Institute for Innovation, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: dasteind@email.unc.edu.
- Eshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
- Eshelman School of Pharmacy, Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Eshelman Institute for Innovation, University of North Carolin…
Förderung
- NINDS NIH HHS
- Eshelman Institute for Innovation, University of North Carolina at Chapel Hill
- Accelerate Brain Cancer Cure
- National Institutes of Health
Zitieren
APA
Zhang, X., Artz, N., Steindler, D. A., Hingtgen, S., & Satterlee, A. B. (2025). Exosomes: Traversing the blood-brain barrier and their therapeutic potential in brain cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2025.189300
Vancouver
Zhang X, Artz N, Steindler DA, Hingtgen S, Satterlee AB. Exosomes: Traversing the blood-brain barrier and their therapeutic potential in brain cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2025. doi:10.1016/j.bbcan.2025.189300
BibTeX
@article{Zhang2025,
author = {Zhang, Xiaopei and Artz, Nichole and Steindler, Dennis A and Hingtgen, Shawn and Satterlee, Andrew Benson},
title = {Exosomes: Traversing the blood-brain barrier and their therapeutic potential in brain cancer},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2025},
doi = {10.1016/j.bbcan.2025.189300}
}
EUVIMED